A study to evaluate prevalence of thrombocytopenia in antenatal patients
DOI:
https://doi.org/10.18203/2320-1770.ijrcog20233312Keywords:
Maternal and fetal outcomes, High risk groups, Reduced platelet countsAbstract
Background: Basically, thrombocytopenia is a hemorrhagic disorder that occurs as a result of reduced platelet counts and this study provides a concise over view about the challenges faced with the antenatals who suffer from thrombocytopenia and related issues. it usually results from various etiological factors which demand proper monitoring and timely management for better maternal and Fetal outcomes. this study focuses on the diagnosis of thromobocytopenia and the causes of it and also the effects.
Methods: Data are collected from both the antenatal women attending outpatient and inpatient department at obstetrics and gynecology department at Narayana Medical College and Hospital, Nellore with total platelet count less than 1,50,000/ul and then they are followed and the details regarding antenatal complications, intrapartum events and fetal outcome are collected from them.
Results: Present study showed that the definite increased risk of preeclampsia, eclampsia, anemia, hypothyroidism, gestational diabetes mellitus, chronic hypertension, overt diabetes, obesity, preterm labor, cesarean section rate, low birth weight babies in elderly primigravidas and anemia, hypothyroidism, preterm labour, low birth babies, NICU admission in teenage primigravidas compared with pregnant in the younger age group.
Conclusions: Timely identification and management of the cause of thrombocytopenia is crucial in the antenatal group of women. Most of the cases of thrombocytopenia are incidental findings with asymptomatic patients. Proper diagnosis and timely interventions are essential for better outcomes in antenatals with thrombocytopenia. gestational thrombocytopenia appears to be the most prevalent causes.
References
Cines DB, Levine LD. Thrombocytopenia in pregnancy. Blood. 2017;130(21):2271-7.
Wang X, Xu Y, Luo W, Feng H, Luo Y, Wang Y, et al. Thrombocytopenia in pregnancy with different diagnoses: Differential clinical features, treatments, and outcomes. Medicine. 2017;96(29):e7561.
Khellaf M, Loustau V, Bierling P, Michel M, Godeau B. Thrombocytopenia and pregnancy. Rev Med Intern. 2012;33(8):446-52.
Levy JA, Murphy LD. Thrombocytopenia in pregnancy. J Am Board Fam Pract. 2002;15(4):290-7.
Boehlen F. Thrombocytopenia during pregnancy. Importance, diagnosis and management Hamostaseologie. 2006;26(1):72-4.
Fogerty AE. Thrombocytopenia in pregnancy: mechanisms and management. Transfus Med Rev. 2018;32(4):225-9.
Jodkowska A, Martynowicz H, Kaczmarek Wdowiak B, Mazur G. Thrombocytopenia in pregnancy- pathogenesis and diagnostic approach. Postepy Hig Med Dosw. 2015;69:1215-21.
McCrae KR. Thrombocytopenia in pregnancy. Hematology Am Soc Hematol Educ Progr. 2010;397-402.
Eslick R, McLintock C. Managing ITP and thrombocytopenia in pregnancy. Platelets. 2020;31(3):300-6.
Committee on Practice Bulletins- Obstetrics. ACOG Practice Bulletin No. 207: Thrombocytopenia in Pregnancy. Obstet Gynecol. 2019;133(3):e181-9.
Egan K, Crowley D, Smyth P, O’Toole S, Spillane C, Martin C, et al. Platelet adhesion and degranulation induce pro-survival and pro-angiogenic signalling in ovarian cancer cells. PLoS One. 2011;6(10).
Nurden AT. Platelets, inflammation and tissue regeneration. Thromb Haemost. 2011;105(1):13-33.
Jin RC, Voetsch B, Loscalzo J. Endogenous mechanisms of inhibition of platelet function. Microcirculation. 2005;12(3):247-58.
Maroney SA, Mast AE. New insights into the biology of tissue factor pathway inhibitor. J Thromb Haemost. 2015;13(S1):S200-7.
Valera M-C, Parant O, Vayssiere C, Arnal J-F, Payrastre B. Physiologic and pathologic changes of platelets in pregnancy. Platelets. 2010;21(8):587-95.
Bujold E, Roberge S, Lacasse Y, Bureau M, Audibert F, Marcoux S, et al. Prevention of Preeclampsia and Intrauterine Growth Restriction With Aspirin Started in Early Pregnancy: A Meta-Analysis. Obstet Gynecol. 2010;116(2).
